wragg
Eli Lilly (NYSE:LLY) shares dipped Monday after a research revealed in The Journal of the American Medical Affiliation indicated that sufferers who have been below the corporate’s weight problems drug, tirzepatide, regained weight after discontinuing the remedy.
The remedy marketed for weight problems as Zepbound led to a imply weight discount of 20.9% over 36 weeks of remedy. Nonetheless, these who switched to a placebo instantly afterward witnessed a 14% weight acquire over 52 weeks, the researchers discovered.
In the meantime, those that remained on the remedy skilled a further 5.5% weight reduction. The peer-reviewed research sponsored by Eli Lilly (LLY) enrolled 670 adults with weight problems or chubby however with out diabetes.
The authors acknowledged the research’s limitations, together with its failure to regulate doses after randomization and think about the results of behavioral remedy on the upkeep of physique weight discount.
A research funded by Novo Nordisk (NVO) (OTCPK:NONOF), LLY’s rival within the weight loss house, additionally indicated final yr that sufferers on the Danish drugmaker’s weight reduction drug semaglutide regained two-thirds of their misplaced physique weight a yr after discontinuing the remedy.